Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Virginia Commonwealth University, Richmond Virgina, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Richmond Virgina
Treatments:ImmunotherapyHospital:Virginia Commonwealth University
Drugs:Journal:Link
Date:Jan 2006

Description:

Patients: This phase 2 study involved 26 patients with advanced cutaneous melanoma (all with the Human Leukocyte Antigen genotype).

Treatment: Treatment consisted of immunotherapy - melanoma peptide vaccination (g209-2M) and low dose interleukin-2.

Toxicity: Toxicities included: grade 3 hypertension, arrhythmia, rash and nausea.

Results: Overall median survival was 10 months and no responses were reported. This study demonstrated that the combination of g209-2M and low-dose IL-2 is not active in melanoma. A preliminary report released subsequent to initiation of this study suggested that the combination of g209-2M and high-dose IL-2 is less effective than previously suggested.

Correspondence: Dr. John D. Roberts





Back